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ABSTRACT 
Background: The duration of spinal anesthesia with prilocaine has been poorly 
documented and no English-language study has been published regarding the 
effects of dexmedetomidine on the duration of anesthesia with spinal prilocaine. 
Objective: The aim of this study was to assess the effects of dexmedetomi- 
dine IV on the duration of action of pri locaine and its associated adverse events 
(AEs) in spinal anesthesia. 
Methods: In this double-blind, prospect ive study, patients classified as 
American Society of Anesthesiologists grade I to II who were to undergo lower 
abdominal, anorectal, or extremity surgery with a spinal anesthetic were 
assigned to 1 of 2 groups. All patients were administered pri locaine 2% for spi- 
nal anesthesia. Within 10 minutes after spinal anesthesia was initiated, group 1 
received a loading dose of dexmedetomidine 1 pg/kg IV, followed by a mainte- 
nance dose of 0.4 pg/kg • h for 50 minutes; group 2 (control) received the same 
amount of physiologic saline in the same time frame. Mean arterial pressure 
(MAP), heart  rate (HR), duration of sensory  and motor blockade, and sedation 
scores were tracked. Patients were observed for 4.5 hours after surgery, with 
follow-ups occurr ing up to 96 hours after surgery. 
Results: Eighty-three patients were assessed for s tudy inclusion, 23 of 
whom were excluded. Sixty patients (42 men, 18 women; mean [SD] age, 
40.56 [16.86] years) were included in the study. MAP was similar in the 
2 groups throughout  the study. Mean (SD) HR was significantly lower in group 
1 compared with group 2 at 20 minutes (70.43 [19.28] vs 77.63 [18.14] beats per 
minute, respectively; P = 0.02). The mean (SD) duration of the pers istence of 
sensory  anesthesia (ie, the time required for the maximal evel of anesthesia 
to regress 2 dermatomes)  was significantly longer in group 1 compared with 
group 2 (148.33 [21.18] vs 122.83 [18.73] minutes; P < 0.001). The mean (SD) 
time to complete abol ishment of motor blockade was also significantly longer 
in group 1 than in group 2 (215.16 [25.10] vs 190.83 [18.57] minutes; P< 0.001). 
The average sedation score in group 1 was significantly higher than in group 2 
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(P < 0.001) during anesthesia. Significantly more patients in group 1 required 
atropine than those in group 2 (9 vs 2 patients; P < 0.001) to treat bradycardia. 
There was no significant between-group difference in the number of patients who 
received ephedrine to treat hypotension. One patient in each group reported 
waist and back pain; 2 patients in each group reported nausea. Shivering 
occurred in 0 and 5 patients in groups 1 and 2, respectively; the between-group 
difference in AEs was not statistically significant. Paresthesia, postdural punc- 
ture headache, allergic reactions, total spinal anesthesia, urinary retention, or 
vomiting--AEs commonly associated with spinal anesthesia--were not observed 
or reported by either group. 
Conclusions: The results of this study suggest hat dexmedetomidine IV 
significantly prolonged the duration of spinal anesthesia and provided asignifi- 
cantly higher level of sedation compared to placebo in this group of adult sur- 
gical patients. The treatment was generally well tolerated in all patients. (Curt 
TherRes Clb~ Exp. 2007;68:313-324) Copyright © 2007 Excerpta Medica, Inc. 
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INTRODUCTION 
Spinal anesthesia has several advantages, including spared spontaneous respira- 
tion, low cost, reduced risk for pulmonary aspiration secondary to vomiting in 
patients whose stomach is full, facilitation of surgery by relaxing the intestines and 
abdominal wall, elimination of intubation, minimal disruption of blood chemistry, 
reduced hemorrhaging during surgery, and earlier return of intestinal motility. 1,2 
However, spinal anesthesia also has complications and contraindications, including 
refusal by the patient, the inability to estimate the duration of surgery, postdural 
puncture headache (PDPH), urinary retention, waist and back pain, paresthesia, 
allergic reactions, total spinal anesthesia, shivering, and vomiting. 1,2 
In order to prolong the duration of spinal anesthesia, sodium bicarbonate, 
carbon dioxide, or vasoconstrictor agents have been added to the local anes- 
thetic, as well as IV clonidine, an c¢2-agonist drug. 2,3 A prospective, double-blind 
study 4was conducted in 2006 in 60 patients undergoing transurethral resection 
of prostate or bladder tumor. The objective of that study was to determine the 
effects of low-dose dexmedetomidine (3 pg) or clonidine (30 pg) on the dura- 
tion of bupivacaine spinal block. The results suggested that dexmedetomidine 
or clonidine, when added to intrathecal bupivacaine, produced similar prolon- 
gation of the duration of the motor and sensory block with preserved hemody- 
namic stability and lack of sedation. 
The duration of spinal anesthesia with prilocaine has been poorly docu- 
mented, and no English-language study has been published regarding the 
effects of dexmedetomidine on the duration of anesthesia with spinal prilo- 
caine according to a literature search of MEDLINE (1965-2007) using key words 
prilocaine, spinal anesthesia, nd dexmedetomidine. In this study, the effects of 
dexmedetomidine IV on the duration of action of prilocaine and its associated 
adverse vents (AEs) were investigated in spinal anesthesia. 
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PATIENTS AND METHODS 
Patients categorized as American Society of Anesthesiologists (ASA) physical 
status I or II 5 who were to undergo lower abdominal, anorectal, or extremity 
surgery under spinal anesthesia were eligible for this double-blind, prospective 
study after providing written informed consent.  The study was conducted 
in 6 months in accordance with the principles of the Declaration of Helsinki 6 
and Good Clinical Practice. 7 Institutional ethics committee approval was ob- 
tained before starting the study. 
Patients with pregnancy, hypovolemia, coagulation disorders, or local infec- 
tion at the surgical site; a history of headache, heart disease, allergy, chronic 
alcohol use or abuse, anemia, congenital heart disease, bundle block, conges- 
tive heart failure, or arrhythmia; and patients who had recently received seda- 
tive drugs or who were receiving antidepressant treatment were not eligible 
for the study. 
Consecutive patients were allocated into 2 groups by the lead study investi- 
gator (M.T.) according to the last digit (odd or even) of their admission umber. 
One investigator (Y.T.), who was not blinded to the treatment groups, prepared 
the 2 study solutions--dexmedetomidine and physiologic saline. Both of the 
solutions were identical in appearance to maintain blinding. The patients and 
the other investigators who were responsible for administering the study solu- 
tions, perioperative patient care, and study follow-up were blind to the treat- 
ment groups. Patients in group 1 received a maintenance dexmedetomidine 
infusion, whereas those in group 2 (control) received physiologic saline at the 
equivalent dose and duration. 
One day before surgery, each patient was visited and their physical status 
and laboratory data were assessed by the anesthesiologist (Y.T.) participating 
in the study. All patients were informed about spinal anesthesia nd signed 
informed consent. None of the patients received premedication. 
On the day of surgery, each patient was admitted to the preoperative prepa- 
ration unit and was hydrated with lactated Ringer solution containing 5% dex- 
trose (10 mL/kg) through avenous catheter inserted in the dorsum of the hand. 
After admission to the operating room, electrocardiography and monitoring of 
blood pressure (BP), heart rate (HR), and peripheral oxygen saturation (SpO2) 
were initiated (KMA 800, PETAS, Ankara, Turkey). Lumbar puncture was per- 
formed using aseptic techniques in the sitting position through the L4 to L5 inter- 
space in the midline using a 25-G Quincke needle (Spinocan, B-Braun Melsungen 
AG, Melsungen, Germany), the tip of which was held parallel to the dural fibers. 
When clear cerebrospinal fluid was observed, 80 mg of prilocaine 2% solution 
was administered into the subarachnoid space. Each patient was then brought 
to the supine position, their head was elevated, and oxygen 3 L/min was admin- 
istered. The duration of surgery for all study patients was estimated to be 60 to 
90 minutes. Based on the tl/2 o[ dexmedetomidine (-2 hours), 8the duration of 
the infusion was to be 60 minutes for both the active drug and the control solu- 
tion. Within 10 minutes after spinal anesthesia was initiated, group 1 received 
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a loading dose of dexmedetomidine 1 1Jg/kg IV, followed by a maintenance dose 
of 0.4 1Jg/kg • h for 50 minutes. In group 2, physiologic saline was administered 
in the same manner. The same anesthesiologist  (M.T.), who was exper ienced in 
spinal anesthesia,  provided anesthes ia  to all of the study patients. 
Sensory blockade was determined using the pin-prick test, and motor  block- 
ade was determined using the Bromage scale 9 (0 = free movement  of the legs 
and feet; 1 = just able to flex the knees, with free movement  of the feet; 2 = 
unable to flex the knees, but with free movement  of the feet; 3 = unable to move 
legs or feet) by a second anesthesiologist  (i.K.), who was blinded to adminis- 
tration. The level of sedation was assessed according to the Ramsay sedation 
scale 1° (1 = patient is anxious and agitated or rest less or both; 2 = patient is 
cooperat ive,  oriented, and tranquil; 3 = patient responds to commands  only; 
4 = patient exhibits a brisk response to light glabellar tap or loud auditory 
stimulus; 5 = patient exhibits a sluggish response to light glabellar tap or loud 
auditory stimulus; 6 = patient exhibits no response).  
During anesthesia,  BP, HR, and SpO 2 were recorded at 5-minute intervals 
for the first 10 minutes, at 10-minute intervals for the remainder  of the first 
hour, at 20-minute intervals for the second hour, and at 30-minute intervals for 
the remainder  of the recording period (4.5 hours). The levels of sensory  and 
motor  blockade were assessed at 2-minute intervals until the maximal  level 
of anesthes ia  was achieved and at 5-minute intervals thereafter. Hypotension 
was defined as a decrease >30% in BP compared  with the initial preoperat ive 
value, and bradycardia was defined as HR <50 beats per minute. Patients who 
developed hypotension were to be administered fluid replacement t reatment  
and ephedr ine IV at bolus doses of 5 mg; those who developed bradycard ia  
were treated with atropine 0.01 mg/kg IV. The t ime to achieve maximal  sensory  
blockade and the duration of motor  blockade were also recorded. The duration 
of the persistence of sensory anesthesia was defined as the t ime required for the 
maximal  level of anesthes ia  to regress 2 dermatomes.  The duration of motor 
blockade was defined as the t ime required to completely eliminate the motor 
blockade (ie, Bromage scale score = 0). 
Tolerability 
AEs, particularly those associated with spinal anesthesia (eg, paresthesia, head- 
ache, allergy, hypotension, bradycardia, nausea, vomiting, shivering, waist and 
back pain, total spinal anesthesia, and difficulty urinating), were also recorded. 
The patients were observed and asked about  AEs for 4 hours in the recovery  
room and were then d ischarged to their wards. The patients were observed at 
4-hour intervals for the first 24 hours and then at 8-hour intervals for 96 hours 
in their wards by another  anesthesiologist  and surgeon (Y.T., E.K.). 
Statistical Analysis 
The Student t test ( independent samples) was used to compare  the data 
(hemodynamic parameters,  age, weight, height, time to the regression by 2 der- 
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matomes of sensory  blockade [TDRT], and time to complete abol ishment of 
motor blockade [CAMB]). Demographic data, AEs, sedation, and sensory  block- 
ade level were analyzed using the Z 2 test. A power analysis indicated that 27 pa- 
tients were needed in each group (co = 0.05, [3 = 0.81); consequently, the study 
was designed with 30 patients in each group. P < 0.05 was considered statisti- 
cally significant. 
RESULTS 
Eighty-three patients were assessed for study inclusion, 23 of whom were 
excluded according to the exclusion criteria. The 60 patients (42 men, 18 wom- 
en; mean [SD] age, 40.56 [16.86] years) included in the study were divided 
equally into 2 groups. The 2 groups were similar in terms of demographic data, 
ASA grade, and the duration of surgery (Table). HR was significantly lower in 
group 1 compared with group 2 at 20 minutes after the initiation of spinal anes- 
thesia (70.43 [19.28] vs 77.63 [18.14] beats per minute, respectively; P = 0.02) 
(Figure 1). There were no significant between-group differences in regard to 
mean arterial pressure (MAP) (Figure 2) or SpO 2 (Figure 3). 
Mean (SD) time to reach peak sensory  level was similar in the 2 groups 
(group 1, 13.50 [6.41] vs group 2, 13.16 [5.49] minutes). Median (range) peak sen- 
sory level was similar in the 2 groups according to the pin-prick test (group 1, 
T10 [T4-T10]; group 2, T10 [T4-T11]). The TDRT was significantly longer in group 
1 than in group 2 (148.33 [21.18] vs 122.83 [18.73] minutes; P< 0.001) (Figure 4). 
Table. Baseline demographic characteristics, ASA grade, and duration of surgery 
in patients receiving prilocaine 2% for spinal anesthesia and maintenance 
anesthesia with dexmedetomidine (group 1) or physiologic saline (group 2) 
(N = 60).* 
Group 1 Group 2 
Variable (n = 30) (n = 30) 
Age, mean (SD), y 40.63 (18.56) 40.50 (15.29) 
Sex, no. (%) 
Male 22 (73.3) 20 (66.7) 
Female 8 (26.7) 10 (33.3) 
Weight, mean (SD), kg 71.03 (13.58) 69.10 (14.04) 
Height, mean (SD), cm 169.70 (5.35) 167.10 (7.14) 
ASA grade, no. (%) 
I 21 (70.0) 22 (73.3) 
II 9 (30.0) 8 (26.7) 
Duration of surgery, mean (SD), rain 71.02 (11.79) 72.50 (14.84) 
ASA = American Society of Anesthesiologists. 
*No significant between-group differences were found. 
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Figure 1. Mean (SD) heart rate by treatment group in adult surgical patients 
randomized to IV dexmedetomidine (group 1) or normal saline (group 2). 
BSA -- before spinal anesthesia; FSA -- fol lowing spinal anesthesia. *P -- 0.02. 
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Figure 2. Mean (SD) arterial pressure (MAP) by treatment group in adult surgical 
patients randomized to IV dexmedetomidine (group 1) or normal saline 
(group 2). BSA = before spinal anesthesia; FSA = fo l lowing spinal 
anesthesia. 
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Figure 3. Mean (SD) peripheral  oxygen saturat ion (SpO2) by t reatment  group in 
adult  surgical patients randomized to IV dexmedetomid ine  (group 1) or 
normal  saline (group 2). BSA -- before spinal anesthesia; FSA -- fo l low ing  
spinal anesthesia. 
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Figure 4. The t ime required for  the maximal level of anesthesia to regress 2 derma- 
tomes and for  complete abol ishment of the motor  blockade in adult  
surgical patients randomized to IV dexmedetomid ine  (group 1) or nor- 
mal saline (group 2). TDRT -- t ime to the regression by 2 dermatomes 
of sensory blockade; CAMB -- t ime to complete abol ishment of motor  
blockade. *P < 0.001. 
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The CAMB was significantly longer in group 1 than in group 2 (215.16 [25.10] vs 
190.83 [18.57] minutes; P < 0.001) (Figure 4). Median (range) sedation level was 
significantly greater in group 1 than in group 2 (3 [2-4] vs 2 [1-2]; P< 0.001). The 
number of patients who received ephedrine was similar in group 1 (3 [10.0%]) and 
group 2 (2 [6.7%]). A significantly greater number of patients in group 1 received 
atropine compared with those in group 2 (9 [30.0%] vs 2 [6.7%]; P = 0.042). 
Tolerability 
Waist and back pain were reported in 1 (3.3%) patient in each group. Nausea 
was reported in 2 (6.7%) patients in each group. No patient in group 1 expe- 
rienced shivering, while shivering occurred in 5 (16.7%) patients in group 2; 
however, the between-group difference was not statistically significant. None of 
the patients in either group reported paresthesia, PDPH, allergy, vomiting, total 
spinal anesthesia, or difficulty urinating. 
DISCUSSION 
Spinal anesthesia has certain advantages. It can be administered rapidly and it 
provides good abdominal relaxation. The blockade caused by spinal anesthesia 
is well controlled, and the toxic effects of the local anesthetics used are less 
frequent and severe than general anesthesia. The onset of spinal anesthesia s 
rapid, and its effects on mental status are minimal. Blood loss is lower with this 
type of anesthesia, nd spinal anesthesia has been found to have protective 
effects against hromboembolism. 1,2 
When a single-dose injection is used for spinal anesthesia, the duration of 
anesthesia s directly associated with the duration of effect of the local anes- 
thetic administered. Prolonging the duration of spinal anesthesia would be 
ideal for surgical interventions with longer durations. Various additives have 
been used to prolong the duration of spinal anesthesia, including vasocon- 
strictive agents, such as epinephrine, phenylephrine, and clonidine. 1,20pioids 
and neostigmine have also been used.  2,11,12 Clinically, cc2-agonists, uch as clo- 
nidine and dexmedetomidine, are being used as adjuvants in anesthesia. 13,14 
The cc2-agonists used in regional anesthesia have been reported to alter the 
characteristics of anesthetic solutions by inducing vasoconstriction, potentiat- 
ing the blockade of C-fibers, or augmenting the effects of local anesthetics by 
positively influencing slow retrograde axonal transport along the nerves at the 
spinal cord level. 15,16 
Subtype-specific cc2-agonists probably provide analgesia nd anesthesia 
without causing any hemodynamic effects by stimulating only the intended 
receptor population. The cc2-adrenergic receptors in the nerve endings may 
contribute to the analgesic effect by preventing norepinephrine r lease. 16-19 
Prilocaine has been used for spinal anesthesia for >30 years. 2° However, until 
2000, prilocaine and its duration of action had been poorly documented for use 
in spinal anesthesia. Ostgaard et al, 21 in a randomized study of 100 patients 
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scheduled for short urologic procedures under spinal anesthesia, reported that 
the mean (SD) duration of sensory blockade and motor blockade with lidocaine 
80 mg and prilocaine 80 mg were 123 (42) and 197 (42) minutes, respectively. 
The double-blind, randomized study by de Weert et a122 reported the mean (SD) 
duration with isobaric 2% lidocaine 4 mL or isobaric 2% prilocaine 4 mL intra- 
thecally, to be 127 (59) and 166 (45) minutes, respectively. We found these dura- 
tions to be 122.83 (18.73) and 190.83 (18.57) minutes in the control group, which 
are in agreement with the literature. In the treated group, dexmedetomidine 
IV significantly prolonged both the time required for the maximal evel of the 
sensory blockade to regress 2 dermatomes and the time for complete reversal 
of motor blockade compared with the control group. These findings may be due 
to the adjunct effect of dexmedetomidine. Dexmedetomidine did not affect he 
time to the onset of the sensory block. Kanazi et al 4 reported that intrathecal 
dexmedetomidine did not produce a significant difference in the time to reach 
peak sensory level. 
The hemodynamic effects of dexmedetomidine are biphasic; when it is 
administered IV, it induces hypotension and bradycardia until the central sym- 
patholytic effect is established, after which it causes decreases in MAP and HR. 
This restricts the use of dexmedetomidine i  outpatient surgery patients, since 
hypotension and bradycardia may occur in the postoperative period. 23-25 The 
prevalence of hypotension after spinal anesthesia, which has been reported 
to be 30% to 40%, has been attributed to sympathetic blockade. 2,26 The preva- 
lence of decreased MAP after dexmedetomidine i fusion was found to be 14%, 
17%, 23%, and 27% at infusion doses of 0.25, 0.5, 1.0, and 2.0 1Jg/kg, respective- 
ly. 24 In our study, the prevalence of hypotension requiring the administration 
of ephedrine was 10.0% in the treatment group and 6.7% in the control group, 
although the between-group difference was not significant. The hypoten- 
sion was attributed to spinal anesthesia reaching its maximal sensory level. 
Hypotension might have been augmented by the added hypotensive ffect of 
dexmedetomidine. However, the low prevalence of hypotension in our study 
may be attributed to providing sufficient preoperative hydration. 
In the literature, the prevalence of bradycardia fter spinal anesthesia was 
reported to be 10% to 15%. 24 The prevalence of reduced HR following dexmede- 
tomidine infusion was reported to be 25%. We observed a significant reduction 
in HR in group 1 compared with group 2 at 20 minutes after the initiation of 
anesthesia. Nine patients in the dexmedetomidine group and 2 patients in the 
control group required atropine. This difference was attributed to the brady- 
cardia-inducing effect of dexmedetomidine. 
Sedation is frequently required uring regional anesthesia for the comfort of 
both the patient and the surgeon. Propofol, midazolam, clonidine, and dexmede- 
tomidine are frequently used with this purpose. 27,28 In studies of dexmedetomi- 
dine, the intended level of sedation was reported to be achieved at doses of 
0.2 to 0.7 1Jg/kg • hr. Sedation was also reported to be deepened with larger 
doses. 23,25 In our study, deeper sedation was induced in group 1 than group 2, 
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indicating that dexmedetomidine may reduce the need for extra sedative 
agents. 
One of the main goals in using sedative agents is to avoid respiratory depres- 
sion. In a previous study, the o~2-adrenergic agonists were found to cause no 
respiratory depression or only minimal depression. 18 In our study, respiratory 
depression was not observed in any of the patients, and no significant between- 
group difference was found in SpO 2 because all patients were administered 
oxygen 3 L/min during the procedures. 
The prevalence of back pain secondary to spinal anesthesia has been found 
to range between 2.5% and 54.0%. 29-31 In our study, the prevalence of back and 
waist pain was 3.3%, which is similar to other reports in the literature. The 
prevalence of shivering after spinal anesthesia has been reported to range 
between 10% and 40%. 32,33 The absence of shivering in group 1 in our study may 
be associated with dexmedetomidine use. In group 2, we observed shivering in 
16.7% of the patients, which is in agreement with the literature. 
After spinal anesthesia, the prevalence ofnausea has been reported to range 
between 2% and 18%, whereas that of vomiting ranged between 0% and 7%. 26 In 
our study, the prevalences of nausea were 6.7% and 0% in group 1 and group 2, 
respectively; these findings are similar to the literature. Complications such as 
paresthesia, PDPH, allergy, total spinal anesthesia, vomiting, and difficulty in 
voiding were not observed in any of our patients. 
Limitations 
The study sample size was small; only 30 patients were included in each 
group. More than one local anesthetic might have been included in the study 
design to give more comparative data. Finally, the patients were not randomly 
assigned to the study groups. Consecutive patients were allocated into groups 
according to the last digit (odd/even) of their admission umber by the study 
supervisor, who was not blinded to the treatment group. A strictly randomized 
blinded patient allocation to the groups might have made the results of this 
study more valuable. 
CONCLUSION 
We found that dexmedetomidine IV prolonged the duration of sensory and 
motor blockade, provided a higher level of sedation, and was well tolerated 
compared with placebo. 
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